These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 30935953)

  • 1. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
    Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

  • 8. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
    Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
    Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
    Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):15-8. PubMed ID: 25768997
    [No Abstract]   [Full Text] [Related]  

  • 13. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
    Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
    Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.